These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 6421734)

  • 1. Nonopsonic phagocytosis of strains of Pseudomonas aeruginosa from cystic fibrosis patients.
    Speert DP; Eftekhar F; Puterman ML
    Infect Immun; 1984 Mar; 43(3):1006-11. PubMed ID: 6421734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mucoid Pseudomonas aeruginosa resists nonopsonic phagocytosis by human neutrophils and macrophages.
    Cabral DA; Loh BA; Speert DP
    Pediatr Res; 1987 Oct; 22(4):429-31. PubMed ID: 2891100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonopsonic phagocytosis of nonmucoid Pseudomonas aeruginosa by human neutrophils and monocyte-derived macrophages is correlated with bacterial piliation and hydrophobicity.
    Speert DP; Loh BA; Cabral DA; Salit IE
    Infect Immun; 1986 Jul; 53(1):207-12. PubMed ID: 2873104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opsonin-independent phagocytosis of Pseudomonas aeruginosa.
    Speert DP; Loh BA; Cabral DA; Eftekhar F
    Antibiot Chemother (1971); 1985; 36():88-94. PubMed ID: 3923915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phagocytosis of mucoid and nonmucoid strains of Pseudomonas aeruginosa.
    Meshulam T; Obedeanu N; Merzbach D; Sobel JD
    Clin Immunol Immunopathol; 1984 Aug; 32(2):151-65. PubMed ID: 6428788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonopsonic antibodies in cystic fibrosis. Pseudomonas aeruginosa lipopolysaccharide-specific immunoglobulin G antibodies from infected patient sera inhibit neutrophil oxidative responses.
    Eichler I; Joris L; Hsu YP; Van Wye J; Bram R; Moss R
    J Clin Invest; 1989 Dec; 84(6):1794-804. PubMed ID: 2512330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opsonization of mucoid and non-mucoid Pseudomonas aeruginosa by serum from patients with cystic fibrosis assessed by a chemiluminescence assay.
    LeBlanc CM; Bortolussi R; Issekutz AC; Gillespie T
    Clin Invest Med; 1982; 5(2-3):125-8. PubMed ID: 6811181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bispecific antibodies overcome the opsonin-receptor mismatch of cystic fibrosis in vitro: restoration of neutrophil-mediated phagocytosis and killing of Pseudomonas aeruginosa.
    McCormick LL; Karulin AY; Schreiber JR; Greenspan NS
    J Immunol; 1997 Apr; 158(7):3474-82. PubMed ID: 9120309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unusual mechanism of pathogenicity of Pseudomonas aeruginosa isolates from patients with cystic fibrosis.
    Tümmler B
    Infection; 1987; 15(4):311-2. PubMed ID: 3117705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of serum opsonic activity in cystic fibrosis with colonization and disease state: measurement of opsonins to Pseudomonas aeruginosa by neutrophil superoxide anion generation.
    Bender JG; Florman AL; Van Epps DE
    Pediatr Res; 1987 Oct; 22(4):383-8. PubMed ID: 2825106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross-sectional and longitudinal studies of naturally occurring antibodies to Pseudomonas aeruginosa in cystic fibrosis indicate absence of antibody-mediated protection and decline in opsonic quality after infection.
    Tosi MF; Zakem-Cloud H; Demko CA; Schreiber JR; Stern RC; Konstan MW; Berger M
    J Infect Dis; 1995 Aug; 172(2):453-61. PubMed ID: 7622889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance of mucoid Pseudomonas aeruginosa to nonopsonic phagocytosis by alveolar macrophages in vitro.
    Krieg DP; Helmke RJ; German VF; Mangos JA
    Infect Immun; 1988 Dec; 56(12):3173-9. PubMed ID: 3141284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Host defenses in patients with cystic fibrosis: modulation by Pseudomonas aeruginosa.
    Speert DP
    Surv Synth Pathol Res; 1985; 4(1):14-33. PubMed ID: 3927464
    [No Abstract]   [Full Text] [Related]  

  • 14. Role of alginate O acetylation in resistance of mucoid Pseudomonas aeruginosa to opsonic phagocytosis.
    Pier GB; Coleman F; Grout M; Franklin M; Ohman DE
    Infect Immun; 2001 Mar; 69(3):1895-901. PubMed ID: 11179370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bactericidal effect of polymorphonuclear leukocytes on Pseudomonas aeruginosa pre-incubated in ofloxacin.
    Nielsen B; Nielsen H
    Acta Pathol Microbiol Immunol Scand B; 1987 Aug; 95(4):227-32. PubMed ID: 3118637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pulmonary disease associated with Pseudomonas aeruginosa in cystic fibrosis: current status of the host-bacterium interaction.
    Pier GB
    J Infect Dis; 1985 Apr; 151(4):575-80. PubMed ID: 3919113
    [No Abstract]   [Full Text] [Related]  

  • 17. Utilization of human respiratory secretions by mucoid Pseudomonas aeruginosa of cystic fibrosis origin.
    Ohman DE; Chakrabarty AM
    Infect Immun; 1982 Aug; 37(2):662-9. PubMed ID: 6811437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pseudomonas-infected cystic fibrosis patient sputum inhibits the bactericidal activity of normal human serum.
    Schiller NL; Millard RL
    Pediatr Res; 1983 Sep; 17(9):747-52. PubMed ID: 6413945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opsonic defect in patients with cystic fibrosis of the pancreas.
    Biggar WD; Holmes B; Good RA
    Proc Natl Acad Sci U S A; 1971 Aug; 68(8):1716-9. PubMed ID: 5001942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction between Pseudomonas aeruginosa and host defenses in cystic fibrosis.
    Marshall BC; Carroll KC
    Semin Respir Infect; 1991 Mar; 6(1):11-8. PubMed ID: 1909452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.